Pioglitazone/glimepiride
Combination of
PioglitazoneThiazolidinedione
GlimepirideSulfonylurea
Clinical data
Trade namesDuetact, Tandemact
AHFS/Drugs.comUK Drug Information
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Pioglitazone/glimepiride, sold under the brand name Duetact among others, is a fixed-dose combination anti-diabetic medication for the treatment of type 2 diabetes.[2][1] It contains the thiazolidinedione pioglitazone and the sulfonylurea glimepiride.[2][1] It is taken by mouth.[2][1]

The most common side effects include upper respiratory tract infections (such as colds), hypoesthesia (reduced sense of touch), bone fractures, weight gain, dizziness, flatulence (gas) and edema (swelling).[1]

Pioglitazone makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.[1] Glimepiride is a sulphonylurea: it stimulates the pancreas to produce more insulin.[1] Pioglitazone/glimepiride was approved for medical use in the United States in July 2006, and in the European Union in January 2007.[1][3][4]

Medical uses

In the United States pioglitazone/glimepiride is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone.[2][3][5]

In the European Union pioglitazone/glimepiride is indicated for the treatment of people with type 2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of pioglitazone and glimepiride.[1]

References

  1. 1 2 3 4 5 6 7 8 9 "Tandemact EPAR". European Medicines Agency (EMA). Retrieved 27 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. 1 2 3 4 "Duetact- pioglitazone and glimepiride tablet". DailyMed. 5 February 2019. Retrieved 27 July 2020.
  3. 1 2 "Duetact approval letter" (PDF). U.S. Food and Drug Administration (FDA). 27 July 2006. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ↑ "Drug Approval Package: Duetact (pioglitazone HCl + glimepiride) NDA #021925". U.S. Food and Drug Administration (FDA). 4 September 2008.
  5. ↑ "Pioglitazone (marketed as Actos, Actoplus Met, Duetact, and Oseni) Inf". U.S. Food and Drug Administration (FDA). 8 September 2016. Retrieved 27 July 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.